drugset / Trial / NCT06543303

Evaluation of BTV100 in Subjects With Dry Eye Disease

NCT06543303

Phase 2 Recruiting 120 enrolled BioTheraVision, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be a randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study to evaluate the efficacy, safety and tolerability of repeat dosing of Cevimeline Ophthalmic Solution compared to the vehicle in subjects with Dry Eye Disease (DED).

Timeline

Start
2024-12-31
Primary completion
2026-02-15
Completion
2026-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cevimeline Small molecule 1 % Other
Subject Cevimeline Small molecule 2 % Other
Subject Cevimeline Small molecule 4 % Other

Indications